CA3011766C - Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione - Google Patents
Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione Download PDFInfo
- Publication number
- CA3011766C CA3011766C CA3011766A CA3011766A CA3011766C CA 3011766 C CA3011766 C CA 3011766C CA 3011766 A CA3011766 A CA 3011766A CA 3011766 A CA3011766 A CA 3011766A CA 3011766 C CA3011766 C CA 3011766C
- Authority
- CA
- Canada
- Prior art keywords
- acid
- crystalline form
- sodium
- luminol
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16000380.2 | 2016-02-16 | ||
| EP16000380 | 2016-02-16 | ||
| PCT/EP2017/000209 WO2017140422A1 (en) | 2016-02-16 | 2017-02-15 | Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3011766A1 CA3011766A1 (en) | 2017-08-24 |
| CA3011766C true CA3011766C (en) | 2023-08-01 |
Family
ID=55361317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3011766A Active CA3011766C (en) | 2016-02-16 | 2017-02-15 | Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11203575B2 (https=) |
| EP (1) | EP3416952B1 (https=) |
| JP (1) | JP6949856B2 (https=) |
| KR (1) | KR102535959B1 (https=) |
| CN (1) | CN109071461B (https=) |
| CA (1) | CA3011766C (https=) |
| ES (1) | ES2796476T3 (https=) |
| WO (1) | WO2017140422A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3511325A1 (en) * | 2018-01-11 | 2019-07-17 | MetrioPharm AG | Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione |
| US20210379063A1 (en) * | 2018-10-26 | 2021-12-09 | Immunopharma Plus D.O.O. | Oral aminodihydrophthalazinedione compositions and their use in the treatment of non-viral hepatitis |
| EP3858328A1 (en) * | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases |
| CN115768402A (zh) * | 2020-03-25 | 2023-03-07 | 麦翠奥制药公司 | 用于治疗急性肺损伤的5-氨基-2,3-二氢-1,4-酞嗪二酮 |
| EP4164651B1 (en) * | 2020-06-10 | 2025-10-15 | MetrioPharm AG | 5-amino-2,3-dihydro-1,4-phthalazinedione for use in the treatment of coronaviral infections |
| US12440488B2 (en) | 2020-12-01 | 2025-10-14 | Reverspah Llc | Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension |
| US20240075029A1 (en) * | 2020-12-02 | 2024-03-07 | Metriopharm Ag | Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743541A (en) * | 1985-07-17 | 1988-05-10 | Mast Immunosystems, Inc. | Luminescent substrate preparation and its use in specific binding assays |
| FR2839155B1 (fr) * | 2002-04-25 | 2005-02-04 | Roc Imp | Procede pour detecter et localiser des traces de sang et compose pour detecter des traces de sang |
| BRPI0307864B1 (pt) * | 2003-11-25 | 2016-01-12 | Univ Rio De Janeiro | processo para formação de hidrazidas a partir de hidrazinas e ácido dicarboxílicos |
| CN100390152C (zh) * | 2006-03-23 | 2008-05-28 | 潘健 | 一种合成3-硝基或3-氨基邻苯二甲酰肼的方法 |
| PL231885B1 (pl) * | 2009-01-16 | 2019-04-30 | Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia | Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie |
| PT2542535E (pt) * | 2010-03-01 | 2014-08-25 | Metriopharm Ag | Formas cristalinas para sal de sódio de 5-amino-2,3-di hidroftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas |
| US20110246075A1 (en) * | 2010-04-01 | 2011-10-06 | Banik Niranjan C | Providing a Transform Function to Produce a Mechanical Property of a Subterranean Structure |
| WO2011123776A2 (en) * | 2010-04-01 | 2011-10-06 | Guthery B Eugene | Method for detecting occult blood |
-
2017
- 2017-02-15 CA CA3011766A patent/CA3011766C/en active Active
- 2017-02-15 EP EP17711562.3A patent/EP3416952B1/en active Active
- 2017-02-15 ES ES17711562T patent/ES2796476T3/es active Active
- 2017-02-15 JP JP2018542754A patent/JP6949856B2/ja active Active
- 2017-02-15 WO PCT/EP2017/000209 patent/WO2017140422A1/en not_active Ceased
- 2017-02-15 KR KR1020187026714A patent/KR102535959B1/ko active Active
- 2017-02-15 CN CN201780023173.7A patent/CN109071461B/zh active Active
- 2017-02-15 US US15/999,050 patent/US11203575B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019504865A (ja) | 2019-02-21 |
| CN109071461B (zh) | 2022-06-21 |
| CA3011766A1 (en) | 2017-08-24 |
| US20200369623A1 (en) | 2020-11-26 |
| US11203575B2 (en) | 2021-12-21 |
| ES2796476T3 (es) | 2020-11-27 |
| EP3416952A1 (en) | 2018-12-26 |
| KR102535959B1 (ko) | 2023-05-23 |
| WO2017140422A1 (en) | 2017-08-24 |
| JP6949856B2 (ja) | 2021-10-13 |
| EP3416952B1 (en) | 2020-04-08 |
| KR20180107278A (ko) | 2018-10-01 |
| CN109071461A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3011767C (en) | Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione | |
| CA3011766C (en) | Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione | |
| EP4178579B1 (en) | 5-amino-2,3-dihydro-1,4-phthalazinedione as glucocorticoid-sparing agent | |
| WO2017202496A1 (en) | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the ligaments of the joints, articular capsules and bursae | |
| JP7807378B2 (ja) | 稀な慢性炎症性肺疾患の治療における５－アミノ－２，３－ジヒドロ－１，４－フタラジンジオンの使用 | |
| HK40001510B (en) | Method for producing a crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione | |
| HK40001510A (en) | Method for producing a crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione | |
| US12616695B2 (en) | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases | |
| HK40001511A (en) | Crystalline form of 5-amino-2,3-dihydrophtalazine-1,4-dione |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210420 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - SMALL Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250129 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250129 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250129 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - SMALL Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260127 |